Get started
Author

Mathias Earl Palmer

Observed names: Mathias E Palmer, Mathias E. Palmer, Mathias Palmer
Institution: Mayo Clinic
Observed institution: Mayo Clinic
ORCID: 0000-0003-1678-3014
Observed ORCID: 0000-0003-1678-3014
OpenAlex ID: A5052306231
Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma
2022 · Michael H. Storandt, Jennifer J. Gile, et al. · Cancers · 17
PDF
Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib following Immunotherapy: A Real World Evidence Study
2023 · Mathias E. Palmer, Jennifer J. Gile, et al. · Cancers · 8
PDF
Outcome of receiving lenvatinib following immunotherapy in patients with advanced hepatocellular carcinoma.
2023 · Jennifer Gile, Mathias Earl Palmer, et al. · Journal of Clinical Oncology · 4
Multisite institutional study of efficacy and safety of cabozantinib following immunotherapy in patients with advanced hepatocellular carcinoma.
2023 · Mathias Earl Palmer, Michael H. Storandt, et al. · Journal of Clinical Oncology · 2
PDF
Outcomes of Post‐Transplant Rh‐ GCSF and Decitabine Maintenance Therapy in Patients With High‐Risk Myeloid Neoplasm
2025 · Mathias Palmer, Anmol Baranwal, et al. · American Journal of Hematology · 1
PDF
Phase 2 study of futibatinib in combination with pembrolizumab in patients with FGF19 expressing advanced hepatocellular carcinoma
2026 · Nguyen H Tran, Mathias E Palmer, et al. · The Oncologist
PDF
Single-arm phase 2 study of the FGFR inhibitor futibatinib (Futi) in combination with pembrolizumab (Pem) in patients with FGF19 expressing advanced or metastatic hepatocellular carcinoma (aHCC).
2026 · Mathias Earl Palmer, Angela Ulrich, et al. · Journal of Clinical Oncology
Durvalumab: A PD-L1 Blocking Antibody for the Treatment of Adult Patients with Locally Advanced or Metastatic Biliary Tract Cancer
2023 · Amit Mahipal, Mathias Palmer, et al. · touchREVIEWS in Oncology & Haematology
PDF
Works count: 8
Citation count: 32
H-index: 3
I10-index: 1
Year
Topic
Type